{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"MOMENTUM-1","nct_id":"NCT06955169","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=momentum-1-nct06955169. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MOMENTUM-1","arms":[{"description":"Study participants receive \\[177Lu\\]Lu-DOTATATE","label":"[177Lu]Lu-DOTATATE","type":"EXPERIMENTAL"},{"description":"Study participants receive systemic Standard of Care (SOC) Therapy. Control Arm participants crossover to \\[177Lu\\]Lu-DOTATATE at progression","label":"Control","type":"OTHER"}],"collaborators":["Novartis Pharmaceuticals"],"completion_date":{"date":"2030-08","type":"ESTIMATED"},"conditions":["Intracranial Meningioma"],"enrollment":{"count":130,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"[177Lu]Lu-DOTATATE","otherNames":["Lutathera"],"type":"DRUG"},{"name":"Standard of Care treatments","otherNames":["Avastin (bevacizumab), Afinitor (everolimus), Sutent (sunitinib)"],"type":"OTHER"}],"last_update":"2026-10-02","lead_sponsor":"RTOG Foundation, Inc.","official_title":"MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Assessed up to 4 years"}],"references":[],"start_date":{"date":"2025-08-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","url":"https://clinicaltrials.gov/study/NCT06955169"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/momentum-1-nct06955169"}